KZIAKazia Therapeutics
Mkt Cap
$12.85MVolume
42,414.0052W High
$39.0552W Low
$2.86PE Ratio
-0.26KZIA Fundamentals
Price
$7.68Prev Close
$7.69Open
$7.7050D MA
$7.44Beta
1.01Avg. Volume
131,314.10P/B
-3.15Kazia Therapeutics to Request FDA Type C Meeting to Discuss Overall Survival Data in GBM and Potential NDA Filing in Alignment with FDA initiative Project FrontRunner
Kazia Therapeutics to Request FDA Type C Meeting to Discuss Overall Survival Data in GBM and Potential NDA Filing in Alignment with FDA initiative Project FrontRunner Kazia Therapeutics to Request...
PR Newswire·3d ago
Kazia Therapeutics and the Hebrew University of Jerusalem Receives a Grant from The Michael J. Fox Foundation to Evaluate the Therapeutic Potential of Paxalisib as a Treatment for Parkinson's Disease
Kazia Therapeutics and the Hebrew University of Jerusalem Receives a Grant from The Michael J. Fox Foundation to Evaluate the Therapeutic Potential of Paxalisib as a Treatment for Parkinson's Disease...
PR Newswire·8mo ago
Kazia Therapeutics announces the launch of a groundbreaking trial with paxalisib in combination with immunotherapy in women with advanced breast cancer
Kazia Therapeutics announces the launch of a groundbreaking trial with paxalisib in combination with immunotherapy in women with advanced breast cancer Kazia Therapeutics announces the launch of a...
PR Newswire·9mo ago
Kazia Therapeutics Announces Closing of $2.0 Million Registered Direct Offering
Kazia Therapeutics Announces Closing of $2.0 Million Registered Direct Offering Kazia Therapeutics Announces Closing of $2.0 Million Registered Direct Offering PR Newswire SYDNEY, Jan. 14, 2025...
PR Newswire·10mo ago
Kazia Therapeutics Announces $2.0 Million Registered Direct Offering
Kazia Therapeutics Announces $2.0 Million Registered Direct Offering Kazia Therapeutics Announces $2.0 Million Registered Direct Offering PR Newswire SYDNEY, Jan. 10, 2025 SYDNEY, Jan. 10, 2025...
PR Newswire·10mo ago
Kazia Therapeutics Provides Update on Paxalisib Regulatory Pathway Following Type C Meeting with FDA
Kazia Therapeutics Provides Update on Paxalisib Regulatory Pathway Following Type C Meeting with FDA Kazia Therapeutics Provides Update on Paxalisib Regulatory Pathway Following Type C Meeting with...
PR Newswire·10mo ago
Kazia Therapeutics to Present Data Highlighting Synergistic Activity Between Paxalisib and Immunotherapy in Immunotherapy-Resistant Triple Negative Breast Cancer Model at the San Antonio Breast Cancer Symposium
Kazia Therapeutics to Present Data Highlighting Synergistic Activity Between Paxalisib and Immunotherapy in Immunotherapy-Resistant Triple Negative Breast Cancer Model at the San Antonio Breast...
PR Newswire·11mo ago
Kazia Therapeutics Announces Granting of Type C Meeting with FDA to Discuss Potential Next Steps for Paxalisib in the Treatment of Newly Diagnosed Glioblastoma Multiforme
Kazia Therapeutics Announces Granting of Type C Meeting with FDA to Discuss Potential Next Steps for Paxalisib in the Treatment of Newly Diagnosed Glioblastoma Multiforme Kazia Therapeutics Announces...
PR Newswire·1y ago
Breast Cancer Awareness Month Sees Biotech Advancements and Worrying Trends for Young Women
Breast Cancer Awareness Month Sees Biotech Advancements and Worrying Trends for Young Women Breast Cancer Awareness Month Sees Biotech Advancements and Worrying Trends for Young Women PR Newswire...
PR Newswire·1y ago
Kazia Therapeutics Announces Presentation of Promising Phase I Data Evaluating Concurrent Paxalisib and Radiation Therapy in Patients with Solid Tumor Brain Metastases or Leptomeningeal Metastases Harboring PI3K Pathway Mutations at the American Society f
Kazia Therapeutics Announces Presentation of Promising Phase I Data Evaluating Concurrent Paxalisib and Radiation Therapy in Patients with Solid Tumor Brain Metastases or Leptomeningeal Metastases...
PR Newswire·1y ago